New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

New peptide receptor radionuclide therapy of invasive cancer cells : in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. / Persson, Morten; Rasmussen, Palle; Madsen, Jacob; Ploug, Michael; Kjaer, Andreas.

I: Nuclear Medicine and Biology, Bind 39, Nr. 7, 10.2012, s. 962-9.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Persson, M, Rasmussen, P, Madsen, J, Ploug, M & Kjaer, A 2012, 'New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts', Nuclear Medicine and Biology, bind 39, nr. 7, s. 962-9. https://doi.org/10.1016/j.nucmedbio.2012.05.007

APA

Persson, M., Rasmussen, P., Madsen, J., Ploug, M., & Kjaer, A. (2012). New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nuclear Medicine and Biology, 39(7), 962-9. https://doi.org/10.1016/j.nucmedbio.2012.05.007

Vancouver

Persson M, Rasmussen P, Madsen J, Ploug M, Kjaer A. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nuclear Medicine and Biology. 2012 okt.;39(7):962-9. https://doi.org/10.1016/j.nucmedbio.2012.05.007

Author

Persson, Morten ; Rasmussen, Palle ; Madsen, Jacob ; Ploug, Michael ; Kjaer, Andreas. / New peptide receptor radionuclide therapy of invasive cancer cells : in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. I: Nuclear Medicine and Biology. 2012 ; Bind 39, Nr. 7. s. 962-9.

Bibtex

@article{fd55a8ab357a48ab849648645377b3d4,
title = "New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts",
abstract = "The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.",
keywords = "Animals, Beta Particles, Cell Transformation, Neoplastic, Colorectal Neoplasms, Dideoxynucleosides, Female, HT29 Cells, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Mice, Molecular Targeted Therapy, Neoplasm Invasiveness, Oligopeptides, Positron-Emission Tomography, Radioisotopes, Receptors, Urokinase Plasminogen Activator, Substrate Specificity",
author = "Morten Persson and Palle Rasmussen and Jacob Madsen and Michael Ploug and Andreas Kjaer",
note = "Copyright {\textcopyright} 2012 Elsevier Inc. All rights reserved.",
year = "2012",
month = oct,
doi = "10.1016/j.nucmedbio.2012.05.007",
language = "English",
volume = "39",
pages = "962--9",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier",
number = "7",

}

RIS

TY - JOUR

T1 - New peptide receptor radionuclide therapy of invasive cancer cells

T2 - in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts

AU - Persson, Morten

AU - Rasmussen, Palle

AU - Madsen, Jacob

AU - Ploug, Michael

AU - Kjaer, Andreas

N1 - Copyright © 2012 Elsevier Inc. All rights reserved.

PY - 2012/10

Y1 - 2012/10

N2 - The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.

AB - The proposition of uPAR as a potential target in cancer therapy is advanced by its predominant expression at the invasive front of colorectal cancer (CRC) and its value as prognostic biomarker for poor survival in this disease. In this study, we provide the first in vivo proof-of-concept for a theranostic approach as treatment modality in a human xenograft colorectal cancer model.

KW - Animals

KW - Beta Particles

KW - Cell Transformation, Neoplastic

KW - Colorectal Neoplasms

KW - Dideoxynucleosides

KW - Female

KW - HT29 Cells

KW - Heterocyclic Compounds, 1-Ring

KW - Humans

KW - Lutetium

KW - Mice

KW - Molecular Targeted Therapy

KW - Neoplasm Invasiveness

KW - Oligopeptides

KW - Positron-Emission Tomography

KW - Radioisotopes

KW - Receptors, Urokinase Plasminogen Activator

KW - Substrate Specificity

U2 - 10.1016/j.nucmedbio.2012.05.007

DO - 10.1016/j.nucmedbio.2012.05.007

M3 - Journal article

C2 - 22739362

VL - 39

SP - 962

EP - 969

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 7

ER -

ID: 45945376